Basic research

Research on the role of SOX9 in regulating metabolic reprogramming in diffuse large B cell lymphoma

  • Yirong ZHANG ,
  • Weiqing WEI ,
  • Jiao MA ,
  • Xue ZHANG
Expand
  • 1.Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    2.Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University College of Basic Medical Sciences, Shanghai 200025, China
MA Jiao, E-mail: drjiaoma@shsmu.edu.cn.
ZHANG Xue, E-mail: xuezhang@shutcm.edu.cn

Received date: 2023-04-06

  Accepted date: 2023-05-22

  Online published: 2023-10-28

Supported by

Natural Science Foundation of Shanghai(23ZR1436100)

Abstract

Objective ·To explore the role played by the differentially expressed SRY-box transcription factor 9 (SOX9) gene in diffuse large B cell lymphoma (DLBCL), particularly in the regulation of metabolic reprogramming in the germinal center B-cell (GCB) like subtype. Methods ·The clinical information and gene expression profile data of 481 DLBCL patients retrieved from the NCICCR-DLBCL database were included. Data analysis and visualisation were performed by using R language version 4.1.3. The classification was performed by using a cell of origin subtype (COO) classification algorithm based on RNA-seq sequencing of expression. ABC/GCB features were used to annotate gene sets, and the classification was verified by gene set enrichment analysis. The ABC and GCB subgroup was dichotomised based on the mean expression of SOX9. Differential analysis was performed by using the DEseq2 package. The relationship between SOX9 and ABC-DLBCL metabolism was analysed by using KEGG (Kyoto Encyclopedia of Genes and Genomes) with the Hallmark annotation set. The survival curves were plotted by using the Kaplan-Meier method. The pan-cancer analysis was performed by using GEPIA2. The microenvironmental scoring analysis was performed by the ESTIMATE package. Results ·Of the 481 DLBCL patient samples, all the patients had RNA-seq expression data, 421 had clinical staging, 335 had international prognostic index (IPI) scores and 234 had survival data. The classification yielded 232 (48.2%) ABC subtypes, 173 (36.0%) GCB subtypes and 76 (15.8%) unclassified, consistent with the proportions declared in the database, and the enrichment analysis was verified to be consistent with the ABC/GCB expression profile. Compared to the high SOX9 expression group, the overall survival was shorter in the low SOX9 expression group and the prognostic score was worse. The pan-cancer analysis showed that this phenomenon was also seen in other tumor types. The differential analysis showed that there were 156 upregulated genes and 1 826 downregulated genes in the GCB subtype in the low SOX9 expression group, compared to the high SOX9 expression group. For metabolic processes, down-regulated genes were enriched in glycolysis. Conclusion ·In the ABC subtype of DLBCL, the SOX9 gene affects the biological features of ABC-DLBCL by regulating metabolic reprogramming, and low expression of SOX9 in DLBCL, possibly caused by high methylation, predicts decreased glycolysis in tumors. The proportion of tumor stromal cells decreases, showing a worse prognosis.

Cite this article

Yirong ZHANG , Weiqing WEI , Jiao MA , Xue ZHANG . Research on the role of SOX9 in regulating metabolic reprogramming in diffuse large B cell lymphoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(10) : 1236 -1244 . DOI: 10.3969/j.issn.1674-8115.2023.10.003

References

1 ROSENWALD A, WRIGHT G, CHAN W C, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346(25): 1937-1947.
2 BEA S. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction[J]. Blood, 2005, 106(9): 3183-3190.
3 PAVLOVA N N, ZHU J J, THOMPSON C B. The hallmarks of cancer metabolism: still emerging[J]. Cell Metab, 2022, 34(3): 355-377.
4 HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
5 CONDELLI V, CRISPO F, PIETRAFESA M, et al. HSP90 molecular chaperones, metabolic rewiring, and epigenetics: impact on tumor progression and perspective for anticancer therapy[J]. Cells, 2019, 8(6): 532.
6 SUN N Y, YANG M H. Metabolic reprogramming and epithelial-mesenchymal plasticity: opportunities and challenges for cancer therapy[J]. Front Oncol, 2020, 10: 792.
7 YIN G, LIANG Y, WANG Y, et al. mTOR complex 1 signalling regulates the balance between lipid synthesis and oxidation in hypoxia lymphocytes[J]. Biosci Rep, 2017, 37(1): BSR20160479.
8 KIRSCH B J, CHANG S J, BETENBAUGH M J, et al. Non-Hodgkin lymphoma metabolism[M]. Cham: Springer International Publishing, 2018.
9 PANDA M, TRIPATHI S K, BISWAL B K. SOX9: an emerging driving factor from cancer progression to drug resistance[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188517.
10 ENJUANES A, FERNàNDEZ V, HERNáNDEZ L, et al. Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma[J]. PLoS One, 2011, 6(5): e19736.
11 BENNETT L B, SCHNABEL J L, KELCHEN J M, et al. DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma[J]. Genes Chromosom Cancer, 2009, 48(9): 828-841.
12 CHENG P F, SHAKHOVA O, WIDMER D S, et al. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma[J]. Genome Biol, 2015, 16(1): 42.
13 PASSERON T, VALENCIA J C, NAMIKI T, et al. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid[J]. J Clin Invest, 2009, 119(4): 954-963.
14 PRéVOSTEL C, RAMMAH-BOUAZZA C, TRAUCHESSEC H, et al. SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/?-catenin signaling[J]. Oncotarget, 2016, 7(50): 82228-82243.
15 SLATTERY M L, HERRICK J S, MULLANY L E, et al. The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer[J]. Genes Chromosom Cancer, 2017, 56(11): 769-787.
16 SCHMITZ R, WRIGHT G W, HUANG D W, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma[J]. N Engl J Med, 2018, 378(15): 1396-1407.
17 LEICH E, SALAVERRIA I, BEA S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations[J]. Blood, 2009, 114(4): 826-834.
18 SOTIRIOU C, WIRAPATI P, LOI S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis[J]. J Natl Cancer Inst, 2006, 98(4): 262-272.
19 REDDY A, ZHANG J, DAVIS N S, et al. Genetic and functional drivers of diffuse large B cell lymphoma[J]. Cell, 2017, 171(2): 481-494.e15.
20 SHAFFER A L, WRIGHT G, YANG L M, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology[J]. Immunol Rev, 2006, 210: 67-85.
21 SUBRAMANIAN A, TAMAYO P, MOOTHA V K, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci USA, 2005, 102(43): 15545-15550.
22 YOSHIHARA K, SHAHMORADGOLI M, MARTíNEZ E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data[J]. Nat Commun, 2013, 4: 2612.
23 JIANG Y W, HATZI K, ELEMENTO O, et al. Enhancer profiling reveals SOX9 as a novel transcription regulator of B cell activation and DLBCL transformation[J]. Blood, 2012, 120(21): 527.
24 SHEN Y J, ZHOU J Q, NIE K, et al. Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas[J]. Blood, 2022, 139(1): 73-86.
25 GOOPTU M, WHITAKER-MENEZES D, SPRANDIO J, et al. Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma[J]. Semin Oncol, 2017, 44(3): 204-217.
26 LAM L T, WRIGHT G, DAVIS R E, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma[J]. Blood, 2008, 111(7): 3701-3713.
27 JIANG Y W, HATZI K, SHAKNOVICH R. Mechanisms of epigenetic deregulation in lymphoid neoplasms[J]. Blood, 2013, 121(21): 4271-4279.
Outlines

/